These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 33351204)

  • 21. Schistosoma mansoni antigens alter the cytokine response in vitro during cutaneous leishmaniasis.
    Bafica AM; Cardoso LS; Oliveira SC; Loukas A; Varela GT; Oliveira RR; Bacellar O; Carvalho EM; Araújo MI
    Mem Inst Oswaldo Cruz; 2011 Nov; 106(7):856-63. PubMed ID: 22124559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LACK-specific CD4(+) T cells that induce gamma interferon production in patients with localized cutaneous leishmaniasis during an early stage of infection.
    Bourreau E; Prévot G; Gardon J; Pradinaud R; Hasagewa H; Milon G; Launois P
    Infect Immun; 2002 Jun; 70(6):3122-9. PubMed ID: 12011006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biochemical analysis and immunogenicity of Leishmania major amastigote fractions in cutaneous leishmaniasis.
    Rafati S; Couty-Jouve S; Alimohammadian MH; Louis JA
    Clin Exp Immunol; 1997 Nov; 110(2):203-11. PubMed ID: 9367403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice.
    Campos-Neto A; Webb JR; Greeson K; Coler RN; Skeiky YA; Reed SG
    Infect Immun; 2002 Jun; 70(6):2828-36. PubMed ID: 12010969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
    Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.
    Azeredo-Coutinho RB; Matos DC; Armôa GG; Maia RM; Schubach A; Mayrink W; Mendonça SC
    Clin Exp Immunol; 2008 Sep; 153(3):369-75. PubMed ID: 18627399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis.
    Kemp M; Hey AS; Kurtzhals JA; Christensen CB; Gaafar A; Mustafa MD; Kordofani AA; Ismail A; Kharazmi A; Theander TG
    Clin Exp Immunol; 1994 Jun; 96(3):410-5. PubMed ID: 8004809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased production of interferon-gamma by Leishmania homologue of the mammalian receptor for activated C kinase-reactive CD4+ T cells among human blood mononuclear cells: an early marker of exposure to Leishmania?
    Bourreau E; Pascalis H; Prévot G; Kariminia A; Jolly N; Milon G; Buffet P; Michel R; Meynard JB; Boutin JP; Aschimoff D; Launois P
    Scand J Immunol; 2003 Aug; 58(2):201-10. PubMed ID: 12869142
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis.
    Vélez ID; Gilchrist K; Martínez S; Ramírez-Pineda JR; Ashman JA; Alves FP; Coler RN; Bogatzki LY; Kahn SJ; Beckmann AM; Cowgill KD; Reed SG; Piazza FM
    Vaccine; 2009 Dec; 28(2):329-37. PubMed ID: 19879995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can interferon-gamma and interleukin-10 balance be associated with severity of human Leishmania (Viannia) braziliensis infection?
    Gomes-Silva A; de Cássia Bittar R; Dos Santos Nogueira R; Amato VS; da Silva Mattos M; Oliveira-Neto MP; Coutinho SG; Da-Cruz AM
    Clin Exp Immunol; 2007 Sep; 149(3):440-4. PubMed ID: 17614975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential effects of antigens from L. braziliensis isolates from disseminated and cutaneous leishmaniasis on in vitro cytokine production.
    Leopoldo PT; Machado PR; Almeida RP; Schriefer A; Giudice A; de Jesus AR; Ho JL; Guimarães LH; Bacellar O; Carvalho EM
    BMC Infect Dis; 2006 Apr; 6():75. PubMed ID: 16638143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
    Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
    Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.
    Nateghi Rostami M; Keshavarz H; Edalat R; Sarrafnejad A; Shahrestani T; Mahboudi F; Khamesipour A
    PLoS Negl Trop Dis; 2010 Oct; 4(10):e845. PubMed ID: 20967288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK.
    Pinto EF; Pinheiro RO; Rayol A; Larraga V; Rossi-Bergmann B
    Infect Immun; 2004 Aug; 72(8):4521-7. PubMed ID: 15271911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal immunization with Leish-111f induces IFN-gamma production and protects mice from Leishmania major infection.
    Sakai SI; Takashima Y; Matsumoto Y; Reed SG; Hayashi Y; Matsumoto Y
    Vaccine; 2010 Mar; 28(10):2207-2213. PubMed ID: 20056184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of DNA/DNA and prime-boost vaccination using LPG3 against Leishmania major infection in susceptible BALB/c mice and its antigenic properties in human leishmaniasis.
    Abdian N; Gholami E; Zahedifard F; Safaee N; Rafati S
    Exp Parasitol; 2011 Mar; 127(3):627-36. PubMed ID: 21187087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimized subunit vaccine protects against experimental leishmaniasis.
    Bertholet S; Goto Y; Carter L; Bhatia A; Howard RF; Carter D; Coler RN; Vedvick TS; Reed SG
    Vaccine; 2009 Nov; 27(50):7036-45. PubMed ID: 19786136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IFNG +874T/A polymorphism is not associated with American tegumentary leishmaniasis susceptibility but can influence Leishmania induced IFN-gamma production.
    Matos GI; Covas Cde J; Bittar Rde C; Gomes-Silva A; Marques F; Maniero VC; Amato VS; Oliveira-Neto MP; Mattos Mda S; Pirmez C; Sampaio EP; Moraes MO; Da-Cruz AM
    BMC Infect Dis; 2007 Apr; 7():33. PubMed ID: 17456233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic application of recombinant Leishmania proteins and evaluation of their in vitro immunogenicity after stimulation of immune cells collected from tegumentary leishmaniasis patients and healthy individuals.
    Lima MP; Costa LE; Lage DP; Dias DS; Ribeiro PAF; Machado AS; Ramos FF; Salles BCS; Fagundes MI; Carvalho GB; Franklin ML; Chávez-Fumagalli MA; Machado-de-Ávila RA; Menezes-Souza D; Duarte MC; Teixeira AL; Gonçalves DU; Coelho EAF
    Cell Immunol; 2018 Dec; 334():61-69. PubMed ID: 30287082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.